SK283045B6 - Perorálny mnohonásobný emulzný cyklosporínový prekoncentrát - Google Patents

Perorálny mnohonásobný emulzný cyklosporínový prekoncentrát Download PDF

Info

Publication number: SK283045B6
Authority: SK; Slovakia
Prior art keywords: cyclosporin; solution; ethanol; vitamin; solvent
Prior art date: 1994-11-21

Application number

SK544-95A

Other languages

English (en)

Slovak (sk)

Other versions

SK54495A3 (en

Inventor

Istv�N Kov�Cs

M�Rta Jusztin

Erzs�Bet Tak�Cs

Zolt�N Bal�Zs

Ildik� Kiss

Zsolt Varga

S�Ndor Jancs�

Csaba Heim

N�E Korcsm�Ros Ildik� K�Nya

Erzs�Bet Erd�H�Ti

M�Rta Jarabin

Original Assignee

Biogal Gy�Gyszergy�R Rt.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-21

Filing date

1995-04-27

Publication date

2003-02-04

1995-04-27 Application filed by Biogal Gy�Gyszergy�R Rt. filed Critical Biogal Gy�Gyszergy�R Rt.

1997-02-05 Publication of SK54495A3 publication Critical patent/SK54495A3/sk

2003-02-04 Publication of SK283045B6 publication Critical patent/SK283045B6/sk

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 60
108010036949 Cyclosporine Proteins 0.000 title claims abstract description 60
229960001265 ciclosporin Drugs 0.000 title claims abstract description 52
229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 51
229930182912 cyclosporin Natural products 0.000 title claims abstract description 29
239000000839 emulsion Substances 0.000 title claims abstract description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
239000004094 surface-active agent Substances 0.000 claims abstract description 25
239000002904 solvent Substances 0.000 claims abstract description 23
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
239000012141 concentrate Substances 0.000 claims abstract description 8
ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims abstract description 4
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 9
235000014113 dietary fatty acids Nutrition 0.000 claims description 8
239000000194 fatty acid Substances 0.000 claims description 8
229930195729 fatty acid Natural products 0.000 claims description 8
-1 glyceride ester Chemical class 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
239000001069 triethyl citrate Substances 0.000 claims description 4
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
235000013769 triethyl citrate Nutrition 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 3
150000004665 fatty acids Chemical class 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 2
125000005907 alkyl ester group Chemical group 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 39
150000001733 carboxylic acid esters Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 description 39
239000002775 capsule Substances 0.000 description 26
239000004480 active ingredient Substances 0.000 description 24
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 22
238000009472 formulation Methods 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000007903 gelatin capsule Substances 0.000 description 15
238000010521 absorption reaction Methods 0.000 description 14
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 13
230000035622 drinking Effects 0.000 description 9
239000003921 oil Substances 0.000 description 9
235000019198 oils Nutrition 0.000 description 9
239000012071 phase Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
239000003981 vehicle Substances 0.000 description 9
239000012528 membrane Substances 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000004627 regenerated cellulose Substances 0.000 description 8
238000011282 treatment Methods 0.000 description 8
230000036765 blood level Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
229930003427 Vitamin E Natural products 0.000 description 6
230000000694 effects Effects 0.000 description 6
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
239000000463 material Substances 0.000 description 6
229940046009 vitamin E Drugs 0.000 description 6
235000019165 vitamin E Nutrition 0.000 description 6
239000011709 vitamin E Substances 0.000 description 6
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 5
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 5
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 5
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
108010019249 cyclosporin G Proteins 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000012456 homogeneous solution Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
229940035044 sorbitan monolaurate Drugs 0.000 description 5
239000001593 sorbitan monooleate Substances 0.000 description 5
235000011069 sorbitan monooleate Nutrition 0.000 description 5
229940035049 sorbitan monooleate Drugs 0.000 description 5
238000003860 storage Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000010685 fatty oil Substances 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
150000002334 glycols Chemical class 0.000 description 4
239000004530 micro-emulsion Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 3
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
239000001570 sorbitan monopalmitate Substances 0.000 description 3
235000011071 sorbitan monopalmitate Nutrition 0.000 description 3
229940031953 sorbitan monopalmitate Drugs 0.000 description 3
239000001587 sorbitan monostearate Substances 0.000 description 3
235000011076 sorbitan monostearate Nutrition 0.000 description 3
229940035048 sorbitan monostearate Drugs 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000003613 bile acid Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
230000005484 gravity Effects 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000007764 o/w emulsion Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229920000151 polyglycol Polymers 0.000 description 2
239000010695 polyglycol Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000013112 stability test Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
QHQZEEGNGSZBOL-UHFFFAOYSA-N 2-(aminomethyl)-2-(hydroxymethyl)propane-1,3-diol Chemical class NCC(CO)(CO)CO QHQZEEGNGSZBOL-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
240000007711 Peperomia pellucida Species 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009704 beneficial physiological effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
108010025899 gelatin film Proteins 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
201000006938 muscular dystrophy Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
230000002182 neurohumoral effect Effects 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000012925 reference material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
235000013616 tea Nutrition 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000004383 yellowing Methods 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Dispersion Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

SK544-95A 1994-11-21 1995-04-27 Perorálny mnohonásobný emulzný cyklosporínový prekoncentrát SK283045B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU9403328A HU215966B (hu)	1994-11-21	1994-11-21	Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum

Publications (2)

Publication Number	Publication Date
SK54495A3 SK54495A3 (en)	1997-02-05
SK283045B6 true SK283045B6 (sk)	2003-02-04

Family

ID=10985774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK544-95A SK283045B6 (sk)	1994-11-21	1995-04-27	Perorálny mnohonásobný emulzný cyklosporínový prekoncentrát

Country Status (16)

Country	Link
US (1)	US5583105A (fr)
EP (1)	EP0712631B1 (fr)
KR (1)	KR100377058B1 (fr)
AT (2)	ATE245994T1 (fr)
CA (1)	CA2145242C (fr)
CZ (1)	CZ286686B6 (fr)
DE (2)	DE69531389T2 (fr)
DK (1)	DK0712631T3 (fr)
ES (1)	ES2202330T3 (fr)
GB (1)	GB2295546B (fr)
HU (1)	HU215966B (fr)
IT (1)	IT1281337B1 (fr)
PL (1)	PL182716B1 (fr)
PT (1)	PT712631E (fr)
SI (1)	SI9500350B (fr)
SK (1)	SK283045B6 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6696413B2 (en) *	1995-06-16	2004-02-24	Hexal Ag	Pharmaceutical preparation with cyclosporin A
DE19521974A1 (de) *	1995-06-16	1996-12-19	Hexal Pharmaforschung Gmbh	Pharmazeutische Zubereitung mit Cyclosporin A
GB2317562B (en) *	1995-07-20	1999-08-18	Danbiosyst Uk	Lipid vehicle drug delivery composition containing vitamin E
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
NZ280689A (en) *	1995-12-15	1997-08-22	Bernard Charles Sherma Sherman	Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
KR19980073479A (ko) *	1997-03-14	1998-11-05	한스루돌프하우스, 니콜케르커	사이클로스포린-함유 연질캅셀제
US5958876A (en) *	1996-06-19	1999-09-28	Novartis Ag	Cyclosporin-containing pharmaceutical compositions
KR0183449B1 (ko) *	1996-06-19	1999-05-01	한스 루돌프 하우스, 니콜 케르커	사이클로스포린-함유 연질캅셀제
CN1494920A (zh) *	1996-06-19	2004-05-12	��˹��ŵ��	含有环孢菌素的软胶囊制剂
JP2001523221A (ja) *	1996-09-01	2001-11-20	ファーモスコーポレイション	親油性物質の促進された生物学的利用能のための固形共沈物
US5891469A (en) *	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5798333A (en) *	1996-09-17	1998-08-25	Sherman; Bernard C.	Water-soluble concentrates containing cyclosporins
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
GB2326337A (en)	1997-06-20	1998-12-23	Phares Pharma Holland	Homogeneous lipid compositions for drug delivery
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
US6028067A (en) *	1997-12-05	2000-02-22	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
US6063762A (en) *	1997-12-05	2000-05-16	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
AU1509799A (en) *	1997-12-05	1999-06-28	Chong Kun Dang Corporation	Pharmaceutical composition containing cyclosporin
WO1999029316A1 (fr) *	1997-12-10	1999-06-17	Severson, Mary, L.	Compositions pharmaceutiques contenant une huile d'acide gras omega-3
ID25908A (id) *	1998-03-06	2000-11-09	Novartis Ag	Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
US20030216303A1 (en) *	1998-03-06	2003-11-20	Michael Ambuhl	Emulsion preconcentrates containing cyclosporin or a macrolide
US7030155B2 (en) *	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
EP1154759B1 (fr)	1998-12-30	2008-08-13	Dexcel Ltd.	Concentre dispersable destine a l'administration d'une cyclosporine
US20080070981A1 (en)	2000-02-23	2008-03-20	Henryk Borowy-Borowski	Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en)	2000-02-23	2003-10-14	National Research Council Of Canada	Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en)	1999-04-02	2000-04-04	National Research Council Of Canada	Water-soluble compositions of bioactive lipophilic compounds
GB9912476D0 (en)	1999-05-28	1999-07-28	Novartis Ag	Organic compounds
DE19925001A1 (de) *	1999-05-31	2000-12-07	Pharma Concepts Gmbh & Co Kg	Flüssiges Konzentrat
KR20020059415A (ko) *	1999-09-27	2002-07-12	스티븐 씨. 큐웨이	토콜-가용성 치료요법제
CA2392353A1 (fr) *	1999-11-22	2001-05-31	Galephar Pharmaceutical Research, Inc.	Compositions pharmaceutiques stables au benzimidazole labile acide
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
US7919113B2 (en) *	1999-12-30	2011-04-05	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Dispersible concentrate lipospheres for delivery of active agents
US20050037073A1 (en) *	2000-01-13	2005-02-17	Alpharx Inc.	Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
AUPR549901A0 (en) *	2001-06-06	2001-07-12	Vital Health Sciences Pty Ltd	Topical formulation containing tocopheryl phosphates
ATE444756T1 (de) *	2000-11-14	2009-10-15	Vital Health Sciences Pty Ltd	Zusammensetzungen umfassend komplexe von tocopherolphosphatderivaten
WO2003011303A1 (fr) *	2001-07-27	2003-02-13	Vital Health Sciences Pty Ltd	Therapie dermique mettant en oeuvre des derives de phosphate d'agents de transfert electroniques
US6960563B2 (en) *	2001-08-31	2005-11-01	Morton Grove Pharmaceuticals, Inc.	Spontaneous emulsions containing cyclosporine
US7141648B2 (en)	2001-10-19	2006-11-28	Isotechnika Inc.	Synthesis of cyclosporin analogs
HRP20040354B1 (en) *	2001-10-19	2012-10-31	Isotechnika Inc.	Novel cyclosporin analog microemulsion preconcentrates
CA2466536C (fr) *	2001-12-13	2012-02-07	Vital Health Sciences Pty Ltd	Transport transdermique de composes
AU2002950713A0 (en) *	2002-08-09	2002-09-12	Vital Health Sciences Pty Ltd	Carrier
WO2004064831A1 (fr) *	2003-01-17	2004-08-05	Vital Health Sciences Pty Ltd	Composes possedant des proprietes antiproliferatives
AU2003901815A0 (en) *	2003-04-15	2003-05-01	Vital Health Sciences Pty Ltd	Phosphate derivatives
US20050074469A1 (en) *	2003-10-03	2005-04-07	Charles Signorino	Stable lipophilic emulsions for acrylic coating and method of making
AU2003267747A1 (en) *	2003-10-14	2005-05-05	Ramesh Varada Bapat	Sterile gelling agents
US7569231B2 (en) *	2004-02-06	2009-08-04	Showa Denko K.K.	Method for stabilizing oil-based thickening gel composition
DK1720551T3 (da)	2004-03-03	2011-05-16	Vital Health Sciences Pty Ltd	Alkaloidformuleringer
US20050277584A1 (en) *	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
US20060088591A1 (en) *	2004-10-22	2006-04-27	Jinghua Yuan	Tablets from a poorly compressible substance
CA2578854A1 (fr) *	2004-10-29	2006-05-11	Novartis Ag	Compositions pharmaceutiques a dispersion spontanee
NZ565049A (en) *	2005-06-17	2012-02-24	Vital Health Sciences Pty Ltd	A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070087962A1 (en) *	2005-10-17	2007-04-19	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
US20090005348A1 (en) *	2005-12-23	2009-01-01	Vital Health Sciences Pty Ltd	Compounds Having Cytokine Modulating Properties
EP1867323A1 (fr) *	2006-06-13	2007-12-19	Farmatron Ltd.	Formulations pharmaceutiques avec pénétration améliorée à travers des barrières biologiques
WO2009117151A2 (fr)	2008-03-20	2009-09-24	Virun, Inc.	Composés contenant des composés non polaires
MX2010010050A (es) *	2008-03-20	2011-03-15	Virun Inc Star	Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
ES2344674B1 (es) *	2008-08-07	2011-06-29	Gp Pharm, S.A.	Composicion farmaceutica inyectable de taxanos.
ES2999020T3 (en)	2010-02-05	2025-02-24	Phosphagenics Ltd	Carrier comprising non-neutralised tocopheryl phosphate
CN103037708B (zh)	2010-03-23	2015-05-20	维尔恩公司	含有蔗糖脂肪酸酯的纳米乳液
EP2552486B1 (fr)	2010-03-30	2020-08-12	Phosphagenics Limited	Timbre transdermique
WO2011162802A1 (fr)	2010-06-21	2011-12-29	Virun, Inc.	Compositions contenant des composés non polaires
AU2011300428B2 (en)	2010-09-07	2016-03-24	Dsm Nutritional Products Ag	Comestible emulsions
WO2012122586A1 (fr)	2011-03-15	2012-09-20	Phosphagenics Limited	Nouvelle composition
KR20140103168A (ko) *	2011-12-16	2014-08-25	알러간, 인코포레이티드	폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
EP2811847B1 (fr)	2012-02-10	2017-12-13	Virun, Inc.	Compositions de boissons comprenant des composés apolaires
ITRM20120331A1 (it)	2012-07-12	2014-01-13	Guidotti & C Spa Labor	Composizioni pediatriche orali liquide contenenti nepadutant.
GB201222455D0 (en) *	2012-12-13	2013-01-30	Perioc Ltd	Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US9351517B2 (en)	2013-03-15	2016-05-31	Virun, Inc.	Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en)	2013-08-08	2017-07-04	Virun, Inc.	Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
US9861611B2 (en)	2014-09-18	2018-01-09	Virun, Inc.	Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US10016363B2 (en)	2014-09-18	2018-07-10	Virun, Inc.	Pre-spray emulsions and powders containing non-polar compounds
CN114712308A (zh)	2015-12-09	2022-07-08	磷肌酸有限公司	药物制剂
EP3558903B1 (fr)	2016-12-21	2024-07-03	Avecho Biotechnology Limited	Procédé de phosphorylation d'un alcool complexe

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE295765C (fr) *
DE298351C (fr) *	1915-04-09
FI65914C (fi) *	1978-03-07	1984-08-10	Sandoz Ag	Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
US4861580A (en) *	1985-10-15	1989-08-29	The Liposome Company, Inc.	Composition using salt form of organic acid derivative of alpha-tocopheral
US5154930A (en) *	1987-03-05	1992-10-13	The Liposome Company, Inc.	Pharmacological agent-lipid solution preparation
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
US5342625A (en) *	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
DE3908047A1 (de) *	1989-03-13	1990-09-20	Desitin Arzneimittel Gmbh	Hochdisperse pharmazeutische zusammensetzung
AU614465B2 (en) *	1989-04-05	1991-08-29	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions
US5364632A (en) *	1989-04-05	1994-11-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions
US5234695A (en) *	1990-07-24	1993-08-10	Eastman Kodak Company	Water dispersible vitamin E composition
HU208491B (en) *	1990-11-27	1993-11-29	Gyogyszerkutato Intezet	Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) *	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
IL101241A (en) *	1992-03-16	1997-11-20	Yissum Res Dev Co	Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
EP0570829B1 (fr) *	1992-05-18	2001-04-25	CicloMulsion AG	Composition pharmacéutique pour administration intraveneuse contenant de la cyclosporine et méthode pour sa préparation
EP1142568A1 (fr) *	1992-09-25	2001-10-10	Novartis AG	Compositions pharmaceutiques à base de cyclosporines
WO1994008605A1 (fr) *	1992-10-16	1994-04-28	Smithkline Beecham Corporation	Microemulsions therapeutiques
WO1994008603A1 (fr) *	1992-10-16	1994-04-28	Smithkline Beecham Corporation	Compositions
WO1995011039A1 (fr) *	1993-10-22	1995-04-27	Hexal Pharma Gmbh	COMPOSITION PHARMACEUTIQUE CONTENANT DE LA CYCLOSPORINE A ET DE L'α-TOCOPHEROL
US5447729A (en) *	1994-04-07	1995-09-05	Pharmavene, Inc.	Multilamellar drug delivery systems

1994
- 1994-11-21 HU HU9403328A patent/HU215966B/hu not_active IP Right Cessation
1995
- 1995-03-21 CA CA002145242A patent/CA2145242C/fr not_active Expired - Fee Related
- 1995-03-31 US US08/414,496 patent/US5583105A/en not_active Expired - Lifetime
- 1995-04-25 CZ CZ19951054A patent/CZ286686B6/cs not_active IP Right Cessation
- 1995-04-27 SK SK544-95A patent/SK283045B6/sk not_active IP Right Cessation
- 1995-05-03 PT PT95106655T patent/PT712631E/pt unknown
- 1995-05-03 ES ES95106655T patent/ES2202330T3/es not_active Expired - Lifetime
- 1995-05-03 EP EP95106655A patent/EP0712631B1/fr not_active Expired - Lifetime
- 1995-05-03 DE DE69531389T patent/DE69531389T2/de not_active Expired - Fee Related
- 1995-05-03 DK DK95106655T patent/DK0712631T3/da active
- 1995-05-03 AT AT95106655T patent/ATE245994T1/de not_active IP Right Cessation
- 1995-05-08 KR KR1019950011130A patent/KR100377058B1/ko not_active Expired - Fee Related
- 1995-11-13 SI SI9500350A patent/SI9500350B/sl not_active IP Right Cessation
- 1995-11-14 GB GB9523295A patent/GB2295546B/en not_active Expired - Fee Related
- 1995-11-20 PL PL95311430A patent/PL182716B1/pl not_active IP Right Cessation
- 1995-11-20 DE DE19543271A patent/DE19543271B4/de not_active Expired - Fee Related
- 1995-11-21 AT AT0189395A patent/AT408945B/de not_active IP Right Cessation
- 1995-11-21 IT IT95MI002411A patent/IT1281337B1/it active IP Right Grant

Also Published As

Publication number	Publication date
US5583105A (en)	1996-12-10
ES2202330T3 (es)	2004-04-01
KR960016903A (ko)	1996-06-17
DK0712631T3 (da)	2003-10-27
PT712631E (pt)	2003-11-28
SI9500350A (en)	1996-06-30
GB2295546A (en)	1996-06-05
ITMI952411A0 (fr)	1995-11-21
AT408945B (de)	2002-04-25
KR100377058B1 (ko)	2003-06-11
EP0712631A3 (fr)	1996-12-04
GB2295546B (en)	1998-07-22
GB9523295D0 (en)	1996-01-17
ATA189395A (de)	2001-09-15
CA2145242C (fr)	2001-08-07
DE69531389D1 (de)	2003-09-04
PL311430A1 (en)	1996-05-27
DE19543271B4 (de)	2006-05-24
HK1016814A1 (en)	1999-11-05
PL182716B1 (pl)	2002-02-28
ITMI952411A1 (it)	1997-05-21
SK54495A3 (en)	1997-02-05
EP0712631A2 (fr)	1996-05-22
HU9403328D0 (en)	1995-02-28
DE19543271A1 (de)	1996-06-05
SI9500350B (sl)	2005-02-28
HU215966B (hu)	1999-07-28
IT1281337B1 (it)	1998-02-18
CZ286686B6 (en)	2000-06-14
EP0712631B1 (fr)	2003-07-30
DE69531389T2 (de)	2004-04-15
ATE245994T1 (de)	2003-08-15
CZ105495A3 (en)	1996-07-17
CA2145242A1 (fr)	1996-05-22

Legal Events

Date	Code	Title	Description
2011-01-04	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20100427

Publication	Publication Date	Title
SK283045B6 (sk)	2003-02-04	Perorálny mnohonásobný emulzný cyklosporínový prekoncentrát
EP0874621B1 (fr)	2003-05-07	COMPOSITIONS PHARMACEUTIQUES SOUS FORME D'EMULSIONS COMPRENANT DE LA [3'-DESOXY-3-OXO-MeBmt]1-[Val]2-CICLOSPORINE
US5589455A (en)	1996-12-31	Cyclosporin-containing soft capsule compositions
EP0711550B1 (fr)	2002-01-16	Compositions pour capsule molle à base de cyclosporine
US6306434B1 (en)	2001-10-23	Pharmaceutical composition comprising cyclosporin solid-state microemulsion
NL194781C (nl)	2003-03-04	Farmaceutisch preparaat voor orale toediening dat een cyclosporine bevat.
WO1996036316A1 (fr)	1996-11-21	Formulations auto-emulsifiantes de medicaments lipophiles
EP0813876B1 (fr)	2002-03-27	Préparations contenant de cyclosporine pour capsules molles
US5958876A (en)	1999-09-28	Cyclosporin-containing pharmaceutical compositions
Cavanak et al.	1986	Formulation of dosage forms
CS230492A3 (en)	1992-12-16	Oral pharmaceutical preparation containing cyclosporin and process forpreparing thereof
CZ83498A3 (cs)	1998-07-15	Přípravek obsahující cyklosporin a způsob jeho přípravy
JP2942556B2 (ja)	1999-08-30	シクロスポリンを含有する新規組成物
US20080064760A1 (en)	2008-03-13	Spontaneously Dispersible Pharmaceutical Composition
SK8702001A3 (en)	2002-01-07	Cyclosporin solution
SK123299A3 (en)	2000-02-14	Pharmaceutical compositions containing cyclosporin
WO2004073693A1 (fr)	2004-09-02	Capsule souple contenant une cyclosporine et son procede de fabrication
AT408520B (de)	2001-12-27	Galenische formulierungen
HK1015277B (en)	2004-04-08	[3'-desoxy-3-oxo-mebmt]1-[val]2-ciclosporin-containing emulsion pharmaceutical compositions
MXPA97008934A (en)	1998-10-15	Self-emulsifying formulations of lipofili drugs
KR19990047897A (ko)	1999-07-05	사이클로스포린 함유 약학적 조성물